J&J Quick Fire winners to innovate and commercialise in Queensland
A new hope in the fight against Alzheimer’s disease, a promising new way to tackle gum disease and a low-cost medical device that could revolutionise the diagnosis of heart damage are the recipients of the inaugural Advance Queensland Johnson & Johnson Innovation QuickFire Challenge.
The 3 winners were selected from a pool of nearly 100 applicants and will each receive $100,000 to spend in Queensland on research and development and commercialisation services that progress their healthcare innovations.
The successful recipients are:
- Medical Devices category: Sydney-based Atomo Diagnostics is developing a prototype device for the early detection of cardiac damage. The device is based on Atomo Diagnostics’ AtomoRapid Point-of-Care technology and will utilise cardiac markers developed by Brisbane-based Anteo Technologies.
- Pharmaceuticals category: Taiwan-based Golden Biotechnology Corporation will look to do pre-clinical testing of a chemical compound, called Antroquinonol, which provides hope as a possible drug for the treatment of Alzheimer’s disease.
- Consumer devices category: Using nanotechnology, Eikonic R&D Pty Ltd has identified a chemical compound that targets the class of bacteria responsible for gum disease and tooth decay.
The winners were announced at the Johnson & Johnson Innovation Partnering Office @QUT which provides access to commercialisation expertise, mentoring and support to nurture and accelerate Queensland’s life sciences industry and build our reputation as a global health innovation leader.
The Johnson & Johnson Innovation Partnering Office @QUT is located at the Institute of Health and Biomedical Innovation in Brisbane.